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ABSTRACT: Fabry disease is caused by mutations in the
gene (GLA) that encodes a-galactosidase A (a-Gal A).
The iminosugar AT1001 (GR181413A, migalastat hydro-
chloride, 1-deoxygalactonojirimycin) is a pharmacological
chaperone that selectively binds and stabilizes a-Gal A,
increasing total cellular levels and activity for some mutant
forms (defined as ‘‘responsive’’). In this study, we developed
ac e l l - b a s e da s s a yi nc u l t u r e dH E K - 2 9 3c e l l st oi d e n t i f y
mutant forms of a-Gal A that are responsive to AT1001.
Concentration-dependent increases in a-Gal A activity in
response to AT1001 were shown for 49 (60%) of 81
mutant forms. The responses of a-Gal A mutant forms
were generally consistent with the responses observed in
male Fabry patient-derived lymphoblasts. Importantly, the
HEK-293 cell responses of 19 a-Gal A mutant forms to a
clinically achievable concentration of AT1001 (10lM)
were generally consistent with observed increases in a-Gal
A activity in peripheral blood mononuclear cells from male
Fabry patients orally administered AT1001 during Phase 2
clinical studies. This indicates that the cell-based responses
can identify mutant forms of a-Gal A that are likely to
respond to AT1001 in vivo. Thus, the HEK-293 cell-based
assay may be a useful aid in the identification of Fabry
patients with AT1001-responsive mutant forms.
Hum Mutat 32:965–977, 2011. & 2011 Wiley-Liss, Inc.
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Introduction
Fabry disease (MIM] 301500) is an X-linked lysosomal storage
disorder caused by mutations in the gene (GLA;MIM] 300644,
RefSeq NM_000169.2) that encodes the lysosomal enzyme
a-galactosidase A (a-Gal A; EC 3.2.1.22) [Desnick et al., 2001].
a-Gal A is responsible for the first step in the catabolism of neutral
glycosphingolipids with terminal a-D-galactosyl residues, primarily
globotriaosylceramide (GL-3, also known as Gb3 or CTH) [Desnick
et al., 2001]. Reduced a-Gal A enzyme activity results in the
accumulation of GL-3 in cells and organs throughout the body,
which is believed to be a primary contributor to the life-threatening
manifestations of Fabry disease, including kidney failure, heart
disease, and stroke [Desnick et al., 2001].
The clinical manifestations of Fabry disease span a broad
spectrum of severity and generally correlate with a patient’s
residual a-Gal A levels [Branton et al., 2002; Desnick et al., 2001].
Many of the currently diagnosed patients are males commonly
referred to as ‘‘classic’’ Fabry patients [Desnick et al., 2001], who
have little or no detectable a-Gal A activity and who are most
severely affected. These patients usually experience disease
symptoms in adolescence, including acroparaesthesias in the
extremities, angiokeratoma, and hypohydrosis. Female patients
may be mildly symptomatic, or as severely affected as ‘‘classic’’
males. Many individuals with Fabry disease present with a
‘‘later-onset’’ form, and typically have higher residual a-Gal A
levels than ‘‘classic’’ patients. Recent studies suggest that there is a
large undiagnosed population of ‘‘later-onset’’ Fabry patients
based on systematic screening in hemodialysis, cardiac, and stroke
clinics [Bekri et al., 2005; Chimenti et al., 2004; Nakao et al., 1995,
2003; Rolfs et al., 2005; Sachdev et al., 2002; Spada et al., 2006].
The iminosugar 1-deoxygalactonojirimycin (DGJ, also referred
to as migalastat) is an analog of the terminal galactose of GL-3
that can selectively and reversibly bind to the active site of wild-
type and mutant forms of a-Gal A [Fan et al., 1999a]. Binding of
DGJ stabilizes a-Gal A, thereby increasing the ability of newly
synthesized enzyme to pass the quality control system of the
endoplasmic reticulum (ER), traffic to lysosomes [Fan et al.,
1999a; Fan and Ishii, 2003; Yam et al., 2005, 2006], and reduce the
storage of lysosomal GL-3 both in cultured cells and in vivo
[Fan et al., 1999a; Ishii et al., 2009; Khanna et al., 2010; Yam et al.,
2005, 2006]. As such, DGJ acts as a ‘‘pharmacological chaperone’’
of a-Gal A. It has been hypothesized that a pharma-
cological chaperone may be a viable treatment for Fabry disease,
serving as an alternative to enzyme replacement therapy for some
patients [Fan et al., 1999a; Fan and Ishii, 2003; Yam et al., 2005,
2006]. Accordingly, DGJ is the active component of an investiga-
tional new drug, migalastat hydrochloride (AT1001, GR181413A),
that currently is in clinical development to evaluate its safety and
efficacy as a potential treatment for Fabry disease [Schiffmann
et al., 2008].
Mutant forms that are most likely to show increased total
cellular a-Gal A activity in Fabry patients treated with AT1001 are
physically unstable, prone to inefficient or aberrant folding, have
deficient lysosomal trafficking, and/or show increased levels in
cultured cells upon binding and stabilization by AT1001. Such
mutant forms are defined as ‘‘responsive’’ [Bernier et al., 2004;
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2004; Ioannou et al., 1998; Ishii et al., 1993, 1996]. Missense
mutations in GLA often lead to the expression of responsive
mutant forms of a-Gal A [Benjamin et al., 2009; Fan et al., 1999a;
Ishii et al., 1996, 2007; Lemansky et al., 1987; Shin et al., 2008;
Yam et al., 2005, 2006]. In addition, some mutant forms of a-Gal
A arising from either in-frame insertions, deletions, or multiple-
site missense mutations of GLA, which affect only a small number
of amino acids (Human Gene Mutation Database; http://
www.hgmd.cf.ac.uk/ac/index.php) and retain sufficient a-Gal A
structure and function, may also be responsive to AT1001
[Benjamin et al., 2009; Desnick, 2004; Desnick et al., 2001;
Garman and Garboczi, 2002, 2004]. In contrast, mutations in GLA
that impair the synthesis of a-Gal A, lead to the absence of
full-length protein (e.g., frame-shift, nonsense, larger deletion
mutations, and large insertions), or that significantly affect
substrate binding or catalytic activity are not expected to result
in mutant forms that can be stabilized by AT1001 [Desnick, 2004;
Desnick et al., 2001; Garman and Garboczi, 2002, 2004; Lai et al.,
2003]. Mutant forms that are not affected by AT1001 are defined
as ‘‘non-responsive.’’
Previous studies have shown that AT1001 increases the cellular
levels and activity of some missense mutant forms of a-Gal A in
cultured cell lines (e.g., lymphoblasts or fibroblasts) derived from
Fabry patients [Benjamin et al., 2009; Fan et al., 1999a; Ishii et al.,
2007; Shin et al., 2007]. The AT1001-mediated increases in a-Gal A
activity were concentration-dependent, consistent across cell lines
and cell types from different patients with the same mutation, and
have been demonstrated for mutant forms of the enzyme that are
associated with both ‘‘classic and ‘‘later-onset’’ Fabry disease
[Benjamin et al., 2009; Ishii et al., 2009; Yam et al., 2005, 2006].
As such, it has been speculated that the cultured cell-based responses
of different mutant forms of a-Gal A to clinically achievable
concentrations of AT1001 may be useful to identify Fabry patients
suitable for treatment with AT1001 [Benjamin et al., 2009; Shin
et al., 2007, 2008]. To date, however, an evaluation of whether the
mutant forms of a-Gal A that are responsive to AT1001 in cultured
cells can also respond in Fabry patients has not been reported. Thus,
we have developed a cell-based assay in HEK-293 cells that can
identify mutant forms of a-Gal A that are responsive to AT1001.
Importantly, this assay does not rely on patient-derived cell lines.
Furthermore, we determined if the responses measured in this assay
can identify mutant forms of a-Gal A that respond to AT1001 in
Fabry patient-derived cell lines and in peripheral blood mono-
nuclear cells (PBMCs) of Fabry patients administered the drug.
Materials and Methods
Materials
The HEK-293 cell line (GripTite
TM 293 MSR) was purchased
from Invitrogen (Carlsbad, CA). AT1001 (DGJ hydrochloride;
migalastat hydrochloride) was synthesized by Cambridge Major
Laboratories (Germantown, WI). The synthetic fluorogenic sub-
strate for a-Gal A, 4-methylumbelliferone-a-D-galactopyranoside
(4-MUG), was manufactured in bulk quantity (100g) by Melford
Laboratories Ltd (Suffolk, UK). All other reagents were purchased
from Sigma-Aldrich (St. Louis, MO) unless otherwise indicated.
Mutagenesis
Full-length cDNA encoding wild-type a-Gal A (GLA, RefSeq
NM_000169.2) was subcloned into the expression vector pcDNA6
(Invitrogen) from pCNX2-GLA [Yasuda et al., 2004]. All
mutations in the GLA cDNA were generated by site-directed
mutagenesis within pcDNA6 following standard molecular
biology protocols. Briefly, specific primer pairs were designed
containing the desired mutation. The mutagenesis was performed
by polymerase chain reaction (PCR) using PfuUltra high-fidelity
DNA polymerase (Stratagene, La Jolla, CA) in a thermocycler (MJ
Research, Waltham, MA). The reactions contained a total volume
of 50ml with the following: 41.5mld H 2O, 5.0ml1 0 PfuUltra HF
reaction buffer, 0.5ml each of Forward (or 50-) and Reverse (or 30-)
primers (50mM), 1ml dNTP mix (containing 10mM each of dA,
dT, dC, dG), 1ml pcDNA6-GLA template (2ng/ml), 0.5ml PfuUltra
HF DNA polymerase. The PCR amplification consisted of 16
reaction cycles (30sec denaturation at 941C; 30sec annealing at
55–601C depending on the specific melting temperature of a given
primer pair; 6min elongation at 681C). Afterward, 0.5ml DpnI
(New England Biolabs, Ipswich, MA) was added to each reaction
and incubated at 371C for 2hr. A volume of 7.5ml for each
mutagenesis reaction was used to transform 50ml DH5a cells
(New England Biolabs). Cells were plated on LB-Agar (Lenox L
Agar) (Invitrogen) with 75mg/ml ampicillin, and incubated at
371C overnight. Bacterial colonies were picked, grown overnight
in liquid Miller’s LB broth (ACROS, Geel, Belgium) with
ampicillin shaking at 371C, and plasmid DNA was extracted using
the QuickLyse Miniprep Kit (Qiagen, Valencia, CA). Mutants were
confirmed by sequencing the full-length GLA cDNA insert on the
pcDNA vector. Large-scale plasmid preparations were made using
the PureYield
TM Plasmid Maxiprep Kit (Promega, Madison, WI).
Stock DNA was diluted to 100mg/ml in water and resequenced
prior to transfection.
Transient Transfection and AT1001 Incubation
HEK-293 cells were seeded in sterile clear-bottom 96-well plates
(Corning Life Sciences, Lowell, MA) at a density of 7,500–
10,000cells/well and incubated at 371C, 5% CO2 for 24hr. For
transfection, pcDNA6 plasmid with a mutated GLA insert was
diluted in fresh serum-free Opti-MEM (Invitrogen) and incubated
with fresh transfection HD reagent at a ratio of 1:3.5 (plasmid
DNA:HD reagent) (Invitrogen) for 5min at room temperature in a
total volume of 300ml. Afterward, 5ml of the freshly prepared
transfection mix (containing 0.1mg of plasmid DNA) were added to
each of 48 wells in the 96-well plate (two mutants/plate). Cells were
incubated at 371C, 5% CO2 for 1hr and then vehicle control (5.5ml
media) or 20-fold concentrated stock 1:3 serial dilutions of AT1001
were added in quadruplicate wells for each transfected mutant
form. The initial concentration range of AT1001 was 50nM to
1mM; if the concentration–response curve did not reach saturation
within this range, the concentration range was adjusted to include
AT1001 concentrations as high as 20mM for subsequent determi-
nations. Cells were then incubated for 4 to 5 days before lysis
and assay. AT1001 concentration–response curves in wild-type and
R301Q transfected cells were run in parallel as transfection and
positive response controls, respectively, in every assay. Parallel
transfection of wild-type GLA was considered to be the most
appropriate transfection control for missense and small deletion or
insertion GLA mutants, as the cDNA sequence differs only by one
or a few base pairs, and it is the most commonly used transfection
control for transiently expressed mutant a-Gal A assays [Fan and
Ishii, 2003; Ishii et al., 2007]. In addition, quantitative real-time
PCR measurement of the amount of plasmid DNA recovered from
HEK-293 cells 5 days after transfection was done for wild-type
and several GLA mutants. These measurements detected GLA
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ground (i.e., pcDNA transfected or untransfected cells), indicating
that the transfection efficiencies across different independent assays
and mutations were generally very good regardless of baseline
activity, protein level, or response to AT1001 (data not shown).
R301Q is an appropriate positive control as its responsiveness to
AT1001 has been well established in cultured cells and in vivo
[Asano et al., 2000; Benjamin et al., 2009; Fan et al., 1999a; Fan
and Ishii, 2003; Ishii et al., 2007, 2009; Shin et al., 2007; Yam et al.,
2005, 2006].
a-Gal A Enzyme Activity Measurement
HEK-293 cells were washed twice with phosphate-buffered
saline (PBS), incubated in 200ml fresh media at 371C, 5% CO2
for 2hr, and washed twice with PBS. Afterward, cells were lysed
in 60ml Lysis Buffer (27mM sodium citrate, 46mM sodium
phosphate dibasic, 0.5% Triton X-100, pH 4.6). Lysates (10ml)
were added to 50ml Assay Buffer (Lysis Buffer without Triton
X-100), containing 6 mM 4-MUG and 117mM N-acetyl-D-
galactosamine (GalNac, an inhibitor of a-N-acetylgalactosaminidase,
a lysosomal enzyme present in the cell lysates that has been shown
to hydrolyze 4-MUG [Mayes et al., 1981]), and incubated at 371C
for 1hr. Stop Solution (0.4M glycine, pH 10.8; 70ml) was then
added and fluorescence read on a Victor plate reader (Perkin-
Elmer, Waltham, MA) at 355nm excitation and 460nm emission.
To correct for endogenous a-Gal A activity in HEK-293 cells,
AT1001 concentration–response curves in pcDNA vector only-
transfected cells were run in parallel and raw fluorescence counts
in lysates from these cells were subtracted from those in mutant-
or wild-type-transfected cells. The resultant specific raw fluores-
cence counts for each individual form of a-Gal A as a function of
AT1001 concentration was determined. A Micro BCA Protein
Assay Kit (Pierce, Rockford, IL) was used according to the
manufacturer’s instructions to determine protein concentration
from 40ml of cell lysate from each well. The total protein
amount in each well was used to normalize enzyme activity.
A 4-methylumbelliferone (4-MU) standard curve ranging from
1.3nM to 30mM was run in parallel for calculation of absolute
a-Gal A activity expressed as nmol of 4-MU released/mg protein/
hr (nmol/mg protein/hr) and further normalized to percentage
of untreated wild-type (% WT) enzyme activity. At least three
independent experiments were carried out for each mutation.
A statistically significant increase in a-Gal A levels in response to
AT1001 was determined by a two-tailed, paired t-test (Po0.05)
comparing the enzyme activity in the absence of AT1001 to the
maximally achieved enzyme activity in the presence of AT1001 for
each mutant form of a-Gal A.
a-Gal A Western Blot
Transfected HEK-293 cells were incubated in the absence or
presence of 0.1 and 1mM AT1001 for 4 to 5 days. After removing
media and washing twice with 200ml PBS, 40ml Lysis Buffer
containing protease inhibitors (Roche) were added to each well of
the 96-well plate and the plate was shaken at room temperature
for 15min to lyse the cells. The total protein concentration in each
well was measured from 10ml of lysate using the MicroBCA
Protein Assay Kit. Remaining lysates were stored at  801C for
Western blot analysis. Briefly, 1mg of total protein was loaded on a
4–12% NuPAGE gradient gel (Invitrogen) and electrophoresed at
150 volts for 90min. Proteins on the gel were then transferred to
nitrocellulose membranes using the iBlot
TM Dry Blotting System
(Invitrogen). Immunoblots were probed with a 1:500 dilution of
rabbit antihuman GAPDH polyclonal antibody (Abcam Inc.,
Cambridge, MA) and a 1:1,250 dilution of rabbit antihuman
a-Gal A polyclonal antibody (SH-006-CR0020-08; provided by
Shire Human Genetic Therapies, Inc., Cambridge, MA) overnight
on a platform shaker. After washing, blots were incubated for
45min with a 1:5,000 dilution of horseradish peroxidase-
conjugated goat antirabbit secondary antibody (Pierce), and were
then developed with enhanced chemiluminescence reagents
(Pierce) and imaged on a Kodak Image Station 4000R (Carestream
Molecular Imaging, Rochester, NY).
Locations of Point Mutations in a-Gal A
The locations of the amino acid residues that have been altered
by site-directed mutagenesis and tested in the HEK-293 cell-based
assay were mapped onto the previously determined structure of
human a-Gal A (PDB:1R47) [Garman and Garboczi, 2004]. The
illustrations of the three-dimensional structures were generated
with SWISS-PDB viewer [Guex and Peitsch, 1997] and rendered
with Persistence of Vision Raytracer (Version 3.6).
Phase 2 Clinical Studies with AT1001 in Fabry Patients
Three Phase 2 clinical trials with AT1001 were conducted
in male patients with Fabry disease (see ClinicalTrials.gov;
NCT00214500, NCT00283959, and NCT00283933). Institutional
review board approval was obtained for all centers involved in
the studies and all patients gave written informed consent to
participate.
a-Gal A Assay in PBMCs
a-Gal A levels in PBMCs were measured in Fabry patients from
the above trials to assess their response to AT1001. Blood was
drawn into an 8-ml Vacutainer
s CPT
TM tube (Becton Dickinson,
Franklin Lakes, NJ) from each patient just prior to the first
administration of AT1001, and at various timepoints afterward in
accordance with the different clinical protocols. PBMCs were
immediately harvested according to the manufacturer’s protocol,
pelleted, and frozen at  801C. Cell pellets were thawed on ice and
lysed by sonication in PBMC Lysis Buffer (2.7mM citric acid,
4.6mM sodium phosphate dibasic, pH 5.5). Lysates were frozen
on a dry ice/ethanol bath and stored at  801C. To assay, lysates
(50ml) were combined with 50ml 117mM GalNac and 50ml5m M
4-MUG (each dissolved in 27mM citric acid, 46mM sodium
phosphate dibasic, pH 4.6; 4-MUG is dissolved in DMSO first
in a ratio of 30mmol/ml). Reaction mixtures were incubated at
371C for 1hr. Afterward, 100ml Stop Solution (0.2M NaOH-
glycine, pH 10.7) was added, and fluorescence was read on a
SPECTRAmax
s Gemini XS Spectrophotometer (Molecular
Devices, Downingtown, PA) at 375nm excitation and 450nm
emission. A 4-MU standard curve ranging from 50nM to 20mM
was run in parallel. The BCA Protein Assay Kit was used to
determine the protein concentration from 25ml of cell lysate.
Absolute a-Gal A activity was expressed as nmol/mg protein/hr
and further normalized to percentage of normal enzyme activity.
Data Analysis
The maximum a-Gal A activity was obtained from the top of
the sigmoidal concentration–response curve after nonlinear regres-
sion analysis in GraphPad Prism, version 4.02 (San Diego, CA).
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of AT1001. The a-Gal A activity limit of quantification (LOQ) in
the HEK-293 cell assay was defined as 300nmol/mg protein/hr
(this value is Z1.645standard deviation of the a-Gal A activity
in pcDNA vector-only transfected cells in Z90% of the
experiments). Thus, any measured or calculated value of mutant
or wild-type a-Gal A activity in the HEK-293 cell-based assay
that was below this LOQ was imputed as a value of zero.
The maximum relative increase was calculated from the maximum
a-Gal A activity in cell lysates after AT1001 incubation divided by
the baseline a-Gal A activity (not calculable for mutant forms with
a baseline activity value of zero). The concentration of AT1001
that resulted in 50% of the maximal increase in a-Gal A activity
(EC50 value) was calculated from the sigmoidal concentration–
response curve by the GraphPad Prism software. The a-Gal A
activity at the clinically achievable concentration of 10mM AT1001
[Schiffmann et al., 2008] was calculated using Equation 1 in
Microsoft Office Excel 2003 or 2007 (Redmond, WA). Analyses to
determine p-values for statistical significance were carried out
using Microsoft Office Excel 2003 or 2007. Analyses to determine
the Pearson correlation coefficient and two-tailed correlation
p-value were carried out using GraphPad Prism, version 4.02.
Equation 1. a-Gal A activity at 10mM AT1001:
Baseline activity1
Maximum activity   Baseline activity
11
EC50
Cmax
where EC50 is the concentration of AT1001 that yields 50% of the
maximal increase in a-Gal A activity and Cmax is 10mM AT1001.
Cmax refers to the approximate average maximum concentration
of AT1001 measured in plasma of Fabry patients following a single
oral administration of 150mg AT1001 [Schiffmann et al., 2008].
Mutation Nomenclature
Nucleotide numbering reflects cDNA numbering with 11
corresponding to the A of the ATG translation initiation codon
in the reference sequence (GLA, RefSeq NM_000169.2). The
initiation codon is codon 1.
Results
Identification of Mutant Forms of a-Gal A That are
Responsive to AT1001
Eighty-one Fabry disease-causing missense mutations (including
two double mutations) were identified in male Fabry patient-
derived lymphoblasts or subjects enrolled in the Phase 2 clinical
trials for AT1001. Each mutation was then introduced individually
by site-directed mutagenesis into a human a-Gal A cDNA residing
in a mammalian expression vector to create the recombinant
expression construct that encoded each of the different mutant
forms of a-Gal A. After transient transfection, HEK-293 cells were
incubated without and with increasing concentrations of AT1001
for 4 to 5 days. The AT1001 potency (EC50 value) and maximal
increase in a-Gal A activity after AT1001 incubation were
determined for each transiently expressed mutant form (Fig. 1).
Overall, 49 of the 81 mutant forms (60%) showed a
concentration-dependent and statistically significant increase in
a-Gal A activity in response to AT1001 in HEK-293 cells (Table 1
and Fig. 2). Baseline a-Gal A activity ranged from 0 to 57% of
wild-type. The maximum a-Gal A activity obtained after
incubation with AT1001 ranged from 1.2 to 132% of wild type.
The maximum relative increase in a-Gal A activity ranged from
1.3-fold for E66Q (c.196G4C) to greater than 20-fold for L300P
Figure 1. Responses to AT1001 for different mutant forms of a-Gal A. Representative a-Gal A activity (expressed as nmol 4-MU released/mg
protein/hr) in lysates from HEK-293 cells transiently transfected with the indicated mutant a-Gal A construct and incubated with increasing
concentrations of AT1001 is shown. AT1001 increased the activity of R301Q (top left panel), R363H (top right panel), and P40S (bottom left panel),
but had no effect on R227Q (bottom right panel). Data points are the mean7SEM of quadruplicate determinations. In the experiments shown,
a-Gal A activity was increased 14.6-fold and 1.9-fold for R301Q and R363H, respectively (relative increase was not calculated for P40S because
its baseline is 0). The EC50 values were 9.3, 5.4, and 170mM for R301Q, R363H, and P40S, respectively. The data shown are representative of 24
(R301Q), 4 (R363H), 4 (P40S), and 3 (R227Q) independent experiments.
968 HUMAN MUTATION, Vol. 32, No. 8, 965–977, 2011Table 1. AT1001-Mediated Responses to AT1001 of Mutant Forms of a-Gal A Expressed in HEK-293 Cells
 AT1001 1AT1001
Protein change cDNA change a-Gal A Activity % WT a-Gal A Activity % WT Relative increase EC50 (mM) n
Wild-type Wild-type 33,21771,077 100.070.0 38,81371,553 11773– – 2 4
p.N34S c.101A4G 0.070.0 0.070.0 0.070.0 0.070.0 – – 8
p.P40S c.118C4T 0.070.0 0.070.0 6,4627940 16.772.7 NC 5927377 4
p.T41I c.122C4T 18,43675,427 43.179.0 29,29373,745 70.4711.1 1.770.2 7.671.7 4
p.H46R c.137A4G 0.070.0 0.070.0 0.070.0 0.070.0 – – 3
p.H46Y c.136C4T 0.070.0 0.070.0 0.070.0 0.070.0 – – 3
p.R49L c.146G4T 0.070.0 0.070.0 370781 1.270.3 NC 4337138 3
p.F50C c.149T4G 0.070.0 0.070.0 0.070.0 0.070.0 – – 3
p.M51K c.152T4A 1,8577358 5.670.5 18,55773,974 56.178.6 9.271.8 15.974.2 3
p.E59K c.175G4A 1,108740 3.670.2 3,7427180 12.270.7 3.970.2 7.271.9 3
p.E66Q c.196G4C 14,7397710 49.173.8 18,3887722 61.273.8 1.370.0 0.570.1 5
p.L89R c.266T4G 0.070.0 0.070.0 0.070.0 0.070.0 – – 3
p.I91T c.272T4C 0.070.0 0.070.0 1,5567162 5.170.8 NC 2.370.9 3
p.D92N c.274G4A 0.070.0 0.070.0 0.070.0 0.070.0 – – 3
p.D92Y c.274G4T 0.070.0 0.070.0 0.070.0 0.070.0 – – 3
p.C94S c.281G4C 0.070.0 0.070.0 0.070.0 0.070.0 – – 9
p.W95S c.284G4C 0.070.0 0.070.0 6727112 2.170.4 NC 7,56074,329 6
p.A97V c.290C4T 1,8987406 5.771.3 15,83273,968 48.0712.5 8.370.5 6.772.2 4
p.R100K c.299G4A 0.070.0 0.070.0 0.070.0 0.070.0 – – 3
p.R100T c.299G4C 0.070.0 0.070.0 0.070.0 0.070.0 – – 3
p.R112C c.334C4T 0.070.0 0.070.0 1,0427202 3.170.6 NC 1,7207991
a 4
p.R112H c.335G4A 0.070.0 0.070.0 5,6767590 19.071.3 17.175.4 19.776.2 3
p.F113L c.337T4C 5,96071,230 17.373.6 23,24471,348 67.677.4 4.070.4 8.070.6 3
p.F113S c.338T4C 0.070.0 0.070.0 0.070.0 0.070.0 – – 3
p.G128E c.383G4A 10,7197883 56.9711.2 16,40971,793 85.8719.4 1.570.1 1.470.6 8
p.L131P c.392T4C 0.070.0 0.070.0 0.070.0 0.070.0 – – 3
p.G138E c.413G4A 0.070.0 0.070.0 0.070.0 0.070.0 – – 3
p.C142R c.424T4C 0.070.0 0.070.0 0.070.0 0.070.0 – – 3
p.A143P c.427G4C 0.070.0 0.070.0 0.070.0 0.070.0 – – 3
p.A143T c.427G4A 15,49972,674 51.975.2 23,13173,312 83.8716.0 1.570.1 8.472.3 6
p.G144V c.431G4T 0.070.0 0.070.0 5,9327890 19.572.6 NC 93.4719.0 4
p.S148N c.443G4A 0.070.0 0.070.0 4,0037693 11.971.3 NC 3607137 3
p.S148R c.444T4G 0.070.0 0.070.0 0.070.0 0.070.0 – – 3
p.W162R c.484T4C 0.070.0 0.070.0 0.070.0 0.070.0 – – 3
p.D170V c.509A4T 0.070.0 0.070.0 0.070.0 0.070.0 – – 3
p.G171D c.512G4A 0.070.0 0.070.0 0.070.0 0.070.0 – – 4
p.C172G c.514T4G 0.070.0 0.070.0 0.070.0 0.070.0 – – 3
p.C172Y c.515G4A 0.070.0 0.070.0 0.070.0 0.070.0 – – 4
p.G183D c.548G4A 0.070.0 0.070.0 2238571,897 75.074.2 NC 68.8716.5 4
p.G183S c.547G4A 1,8887116 5.970.5 27,61474,530 84.9712.5 14.371.1 25.276.9 3
p.C202Y c.605G4A 0.070.0 0.070.0 0.070.0 0.070.0 – – 6
p.P205R c.614C4G 0.070.0 0.070.0 0.070.0 0.070.0 – – 9
p.P205T c.613C4A 5,5247747 18.272.8 40,17876,172 132721 7.671.5 15.674.3 4
p.Y207C c.620A4G 0.070.0 0.070.0 8487176 2.770.8 NC 5477351 3
p.Y207S c.620A4C 3647100 1.170.4 4,1957460 12.871.9 13.572.4 66.4726.6 5
p.N215S c.644A4G 4,8987814 15.772.4 16,4007395 53.272.4 3.570.5 5.070.7 3
p.H225R c.674A4G 0.070.0 0.070.0 4,3507366 15.171.0 NC 502787 3
p.W226R c.676T4C 0.070.0 0.070.0 0.070.0 0.070.0 – – 4
p.R227Q c.680G4A 0.070.0 0.070.0 0.070.0 0.070.0 – – 4
p.S235C c.704C4G 0.070.0 0.070.0 1,0287146 3.170.5 NC 6287211 5
p.D244N c.730G4A 13,3947820 43.271.5 22,94871,763 73.972.2 1.770.0 2.070.8 3
p.P259R c.776C4G 8,58571131 28.174.6 40,72471,869 132710 4.970.5 16.872.7 3
p.N263S c.788A4G 1,9287436 6.571.4 27,45873,232 92.379.1 14.972.2 13.571.6 3
p.D264V c.791A4T 0.070.0 0.070.0 0.070.0 0.070.0 – – 3
p.D266V c.797A4T 0.070.0 0.070.0 0.070.0 0.070.0 – – 3
p.G271C c.811G4T 0.070.0 0.070.0 0.070.0 0.070.0 – – 4
p.G271V c.812G4T 0.070.0 0.070.0 0.070.0 0.070.0 – – 5
p.N272K c.816C4A 0.070.0 0.070.0 0.070.0 0.070.0 – – 3
p.S276G c.826A4G 0.070.0 0.070.0 4,492741 12.772.5 NC 24.376.8 7
p.Q279E c.835C4G 5,1387854 16.672.5 32,04878,092 104725 6.170.9 8.871.3 4
p.W287C c.861G4C 0.070.0 0.070.0 5,8097973 16.471.1 NC 6,72772,634
a 3
p.A288P c.862G4C 0.070.0 0.070.0 4,8567650 13.672.3 NC 51723 3
p.I289F c.865A4T 0.070.0 0.070.0 4,900790 14.371.4 NC 209753
p.F295C c.884T4G 1,2577171 4.170.3 13,4827982 44.073.3 12.071.4 38.879.5 3
p.M296I c.888G4A 5,9097802 19.573.5 36,47071,157 11875 6.271.1 3.070.4 3
p.M296V c.886A4G 5,57571837 18.376.5 38,39771,949 126714 7.671.9 2.570.2 3
p.L300P c.899T4C 8647260 2.970.9 18,58472,654 62.979.0 24.573.4 16.471.8 3
p.R301Q c.902G4A 1,8547117 5.670.3 27,76571,060 83.771.9 16.071.0 7.770.4 24
p.V316E c.947T4A 0.070.0 0.070.0 542799 1.870.3 NC 64.4731.2 7
p.N320Y c.958A4T 0.070.0 0.070.0 10,1817631 29.673.5 NC 7387133
a 3
HUMAN MUTATION, Vol. 32, No. 8, 965–977, 2011 969(c.899T4C) and G328A (c.983G4C) (mutant forms with zero a-
Gal A activity at baseline were excluded from this analysis). The EC50
values ranged from 0.5mM for E66Q to greater than 800mMf o r
W95S (c.284G4C), R112C (c.334C4T), and W287C (c.861G4C).
Interestingly, 22 of the 54 mutant forms with baseline activity
below the limit of quantification were responsive, whereas 32
showed no response to AT1001 at any concentration tested
(Table 1). In contrast, all of 27 mutant forms with quantifiable
baseline a-Gal A activity were responsive to AT1001. However,
wild-type a-Gal A transiently expressed in HEK-293 cells did not
consistently show a concentration-dependent increase in activity
after incubation with AT1001 (Table 1, also see Discussion).
Sixteen of the mutant forms that were responsive had AT1001
EC50 values of less than or equal to 10mM (Table 1 and Fig. 2).
Table 1. Continued
 AT1001 1AT1001
Protein change cDNA change a-Gal A Activity % WT a-Gal A Activity % WT Relative increase EC50 (mM) n
p.G325D c.974G4A 0.070.0 0.070.0 8,43971,441 26.277.2 NC 4307144
a 3
p.G328A c.983G4C 1,3207136 3.970.1 26,5347718 79.075.7 21.071.9 31.373.8 3
p.R342Q c.1025G4A 0.070.0 0.070.0 1,1757137 4.470.4 NC 95.0739.3 4
p.R356W c.1066C4T 2,3527276 7.671.4 23,72072,474 75.6711.6 10.171.3 5.470.6 3
p.E358A c.1073A4C 6397200 1.870.4 8,6807902 26.974.2 16.074.4 16.475.4 4
p.E358K c.1072G4A 0.070.0 0.070.0 1,4177136 3.770.5 NC 281732 4
p.R363C c.1087C4T 2,3857119 7.570.7 13,60371,559 42.073.9 5.570.4 3.770.3 3
p.R363H c.1088G4A 8,30272,086 24.176.8 25,72172,292 73.475.3 3.370.5 16.776.5 4
p.P409A c.1225C4G 8347116 2.870.5 12,57272,254 42.077.8 15.371.6 11.371.9 3
p.L415P c.1244T4C 0.070.0 0.070.0 0.070.0 0.070.0 – – 7
p.D55V/Q57L c.164A4T/170C4T 0.070.0 0.070.0 5,5577800 16.971.9 NC 29.4710.8 4
p.L120P/A121T c.359T4C/361G4A 0.070.0 0.070.0 0.070.0 0.070.0 – – 4
Nucleotide numbering reflects cDNA numbering with 11 corresponding to the A of the ATG translation initiation codon in the reference sequence (GLA, RefSeq
NM_000169.2). The initiation codon is codon 1. The a-Gal A activity (1AT1001) is the maximum a-Gal A activity determined as described in Materials and Methods. For
mutant forms with significant increases, a corresponding EC50 value for AT1001 was calculated. For mutant forms with EC50 values 4 800mM, the maximum a-Gal A activity
values (1AT1001) are those measured at the highest tested concentrations of AT1001; these EC50 values are extrapolated because of incomplete saturation at the tops of the
concentration–response curves.
aThe top of the AT1001 concentration–response curve was 10mM. Data are expressed as the mean7SEM of ‘‘n’’ independent experiments. Activity below the LOQ is indicated
as 0.070.0. NC refers to ‘‘not calculable.’’ — indicates no significant increase in a-Gal A activity seen.
Indicates Po0.05, indicates Po0.01, indicates Po0.001 for enzyme activity (nmol of free 4-MU released/mg protein/hr) measured in lysates of cells incubated in the
presence of AT1001 compared to the baseline activity. Significance was determined by two-tailed, paired t-test.
Figure 2. AT1001 increases the activity of different a-Gal A mutant forms with varying magnitude and potency. Top panel: Eighty-one mutant
forms were evaluated in the HEK-293 cell-based assay for response to incubation with AT1001. The average baseline (open bars) and maximally
increased (blue/dark bars) a-Gal A activity in the absence or presence of AT1001, respectively, are shown. The data have been normalized to the
a-Gal A activity of untreated wild-type. Bottom panel: The average EC50 values (expressed asmM) for AT1001 to increase the a-Gal A activity of
each mutant form are shown. For both panels, a-Gal A mutant forms were plotted in order of their positions on the amino acid sequence. Bars
represent mean7SEM of at least three independent experiments conducted for each mutant form. Mutant forms with no associated bar did not
have any quantifiable baseline a-Gal A activity nor response to AT1001 at the concentrations tested. [Color figures can be viewed in the online
issue, which is available at www.wiley.com/humanmutation.]
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To determine if the increases in a-Gal A activity seen in the
HEK-293 cell lysates were accompanied by increases in cellular
levels of the enzyme, a-Gal A protein levels were measured directly
by Western blotting for a subset of mutant forms. The Western
blot results were generally consistent with the enzyme assay
results. As shown in Figure 3, mutant forms that were increased by
AT1001 in the enzyme assay consistently showed robust increases
in a-Gal A protein levels (e.g., R301Q [c.902G4A] and N215S
[c.644A4G]). Similarly, mutant forms that were not increased by
AT1001 in the enzyme assay generally showed little to no increase
in protein level by Western blot (D92Y [c.274G4T] and L415P
[c.1244T4C]). However, for some mutant forms such as C94S
(c.281G4C), G171D (c.512G4A), and G271C (c.811G4T),
activity was not increased by AT1001 in the enzyme assay, but
robust increases in protein levels were observed. Although these
mutant forms are likely to be catalytically inactive as indicated by
a lack of baseline enzyme activity (Table 1) and as suggested by
amino acid substitution within or near critical a-Gal A structural
determinants [Garman and Garboczi, 2004], the increase in
protein levels shown by Western blot suggests that they retain the
ability to bind to AT1001.
Locations of Point Mutations in Mutant Forms of a-Gal A
The locations of the residues affected by single missense mutations
were highlighted in the monomeric a-Gal A protein structure to
assess if structural determinants can be identified for response to
AT1001 (Fig. 4) [Garman and Garboczi, 2004]. Residues mutated in
responsive mutant forms of a-Gal A were found throughout the
(b/a)8 domain and the C-terminal antiparallel b-sheet domains,
indicating that they occur throughout the full-length protein
(Fig. 4A). In contrast, many residues that are mutated in
nonresponsive forms of a-Gal A were located within, or in close
proximity to, the active site (Fig. 4B). However, several other residues
mutated in nonresponsive forms were located elsewhere throughout
the full-length protein without a straightforward structural relation-
ship. Interestingly, mutation at some sites, such as F113 generated
both responsive (F113L, c.337T4C) and nonresponsive mutant
forms (F113S, c.338T4C). These observations further support the
need for empirical testing of each Fabry disease-causing mutant form
of a-Gal A to identify those that are responsive to AT1001.
Comparison of the Mutant a-Gal A Responses Observed
in HEK-293 Cells and in Fabry Patient Lymphoblasts
Previous studies have shown that AT1001 increases the cellular
levels and activity of some missense mutant forms of a-Gal A in
Figure 3. Western blot results for representative mutant forms of
a-Gal A. HEK-293 cells transiently transfected with the indicated
mutant forms of a-Gal A were incubated for 4 to 5 days without or with
0.1 or 1mM AT1001 (represented by the numbers above the bands).
Cell lysates were prepared as described for the enzyme assay and
total protein concentrations were measured. An equal amount of total
protein (1mg) was loaded into each lane and Western blotting was
performed according to standard protocols (see Materials and
Methods). Mutant forms that showed a positive response to AT1001
in the a-Gal A activity assay generally showed increases in a-Gal A
protein levels after incubation with AT1001. Those showing an
increase in the protein but no increase in the enzyme activity assay
after incubation with AT1001 are indicated by an asterisk (). Western
blots of GAPDH as an additional control for equal protein loading in
each lane are also provided. Representative blots of pcDNA only and
wild-type GLA transfected HEK-293 cells are provided as negative and
positive controls. The data for the controls and for each mutant form
are representative of at least three independent experiments with
similar results.
Figure 4. Locations of residues with point mutations in mutant
forms of a-Gal A. Eighty-one amino acid residues corresponding to the
missense mutations tested in the HEK-293 cell-based assay were
mapped onto the structure of the a-Gal A monomer. The a-Gal A
monomeric structure is shown in ribbon representation with the
bound galactose ligand and affected residues displayed in stick
format. Residues with point mutations in AT1001-responsive (A) and
nonresponsive (B) mutant forms of a-Gal A are colored green and red,
respectively.
HUMAN MUTATION, Vol. 32, No. 8, 965–977, 2011 971lymphoblasts derived from Fabry patients [Benjamin et al., 2009;
Fan et al., 1999a; Ishii et al., 2007; Shin et al., 2007]. To assess
if the concentration-dependent, AT1001-mediated increases in
a-Gal A activity seen in the HEK-293 cell-based assay are
consistent with those published previously in male Fabry patient
lymphoblasts [Benjamin et al., 2009], the responses of 75 different
mutant forms that have been tested in both cell types were
compared. As shown in Figure 5A, 44 of 75 mutant forms
consistently showed a significant response to AT1001 in both cell
types. Twenty-four mutant forms consistently did not respond
to AT1001 in either cell type. Seven mutant forms showed
inconsistent results in the two assays (Fig. 5A). Five of these, N34S
(c.101A4G), R100K (c.299G4A), D170V (c.509A4T), C172Y
(c.515G4A), and P205R (c.614C4G) were responsive in patient-
derived lymphoblasts only, but with low baseline activity
(generally o1% of wild type) and small increases in a-Gal A
levels (below 3% of wild type), or relatively high EC50 values
(4300mM) [Benjamin et al., 2009]. Two (G128E [c.383G4A]
and G183S [c.547G4A]) were responsive in the HEK-293 cell-
based assay, but not in the patient lymphoblasts (see Discussion).
The degree of consistency between these two sets of results for
these 75 mutant forms was evaluated in two ways: first by
correlation analysis, and second by calculating the sensitivity
and specificity [Altman and Bland, 1994a,b] of the comparison.
Correlation analysis showed that the baseline a-Gal A activity, the
maximum a-Gal A activity after AT1001 incubation, and the
potency (Fig. 5B) of the AT1001-mediated response were signi-
ficantly correlated (Pearson correlation coefficients [r] were 0.760
[n575], 0.751 [n575], and 0.793 [n544], respectively, with two-
tailed P-values o0.0001 for each) between the HEK-293 cell and
the patient lymphoblast assays. The sensitivity of the HEK-293 cell
results in this comparison to male Fabry patient lymphoblast results
was calculated to be 0.90 (44C4950.90). The specificity of the
HEK-293 cell results in this comparison to the male Fabry patient
lymphoblast results was calculated to be 0.92 (24C2650.92).
Collectively, these results indicate a high degree of consistency in the
responsiveness of a-Gal A mutant forms as shown in the HEK-293
cell-based assay and in male Fabry patient lymphoblasts.
Comparison of the Mutant a-Gal A Responses Observed
in HEK-293 Cells and in PBMCs of Fabry Patients Treated
with AT1001
To determine if the HEK-293 cell-based assay can be used to
identify mutant forms of a-Gal A that are most likely to respond
to AT1001 in vivo, the degree of consistency between the HEK-293
cell-based assay results and the observed responses of mutant
a-Gal A in PBMCs of male Fabry patients after oral administra-
tion of AT1001 was evaluated. To this end, the HEK-293 cell a-Gal
A activity at the clinically achievable concentration of 10mM
Figure 5. The mutant a-Gal A responses to AT1001 in HEK-293 cells are comparable to those from Fabry patient lymphoblasts. A: The HEK-293
cell and Fabry patient lymphoblast [Benjamin et al., 2009] average baseline and maximally increased a-Gal A activity after AT1001 incubation are
shown for 51 different mutant forms that were responsive in either assay (the data are not shown for 24 other mutant forms that consistently did
not respond to AT1001 in both assays). The HEK-293 cell data have been normalized to the baseline a-Gal A activity in wild-type-transfected HEK-
293 cells. The patient lymphoblast data have been normalized to the baseline a-Gal A activity in normal human lymphoblasts. B: Correlation analysis
of the average EC50 values (expressed as the logEC50 [M]) for AT1001-increased a-Gal A activity of 44 different mutant forms that were responsive
in both assays is shown. The logEC50 values of the AT1001-mediated responses were significantly correlated (Pearson correlation coefficient [r]
was 0.793 with a two-tailed P-value of o0.0001) between the HEK-293 cell and the patient lymphoblast assays. Significant correlations of the
baseline a-Gal A activity and the maximum a-Gal A activity after AT1001 incubation were also found between these two assays (Pearson
correlation coefficients [r] were 0.760 and 0.751, respectively, with two-tailed P-values o0.0001 and n575 for each; plots not shown).
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HUMAN MUTATION, Vol. 32, No. 8, 965–977, 2011 973AT1001 [Schiffmann et al., 2008] was determined (see Materials
and Methods) for the 19 mutant forms of a-Gal A represented in
the FAB-CL-201, FAB-CL-202, and FAB-CL-203 clinical studies.
Then, the a-Gal A responses from HEK-293 cells were compared
to the patient PBMC a-Gal A responses from the Phase 2 studies
(Table 2). The degree of consistency between these two sets of
results was first evaluated by calculating the sensitivity and
specificity of the HEK-293 cell-based results in this comparison
for these 19 mutant forms. Second, the degree of consistency was
evaluated by correlation analysis.
Fourteen male Fabry patients representing 11 different mutant
forms showed positive PBMC a-Gal A responses to oral
administration of AT1001 (defined as an increase in a-Gal A
levels of at least 3% of normal; also referred to as a ‘‘good’’ a-Gal
A response) (Table 2). Furthermore, 3 of these 11 mutant forms
showed in vivo responses to AT1001 in two different patients.
Those same 11 mutant forms consistently had responses to 10mM
AT1001 that were statistically significant in the HEK-293 cell-
based assay. Thus, the sensitivity of the HEK-293 cell-based assay
results in comparison to male patient PBMC a-Gal A responses
for this small number of mutant forms shared between the two
datasets was calculated to be 1.0 (11C1151.0).
Eight male Fabry patients representing eight different
mutant forms showed ‘‘non/limited’’ PBMC a-Gal A responses
to oral administration of AT1001 (defined as an increase in a-Gal
A levels of less than 3% of normal) (Table 2). Consistently, 7 of
those 8 mutant forms of a-Gal A did not have a statistically
significant increase in a-Gal A activity after incubation with
10mM AT1001 in the HEK-293 cell-based assay. However, the
results were inconsistent for one mutant form of a-Gal A, F295C
(c.884T4G). F295C did not show a ‘‘good’’ response in PBMCs
from a patient with this mutation when he was receiving a dose of
150mg AT1001 every other day. In contrast, this mutant form did
show a statistically significant response to 10mM AT1001 in the
HEK-293 cell-based assay. Thus, the specificity of the HEK-293
cell-based assay results in comparison to male patient PBMC
a-Gal A responses for this small number of mutant forms
shared between the two datasets was calculated to be 0.88
(7C850.88).
The consistency of the HEK-293 cell-based and in vivo
responses was further evaluated by correlation analysis. This
analysis showed that the baseline a-Gal A activity and the a-Gal A
activity after treatment with AT1001 (i.e., after AT1001 oral
administration to patients in vivo versus after 10mM AT1001
incubation in vitro) were significantly correlated (Pearson
correlation coefficients [r] were 0.639 and 0.559, respectively,
with two-tailed P-values o0.01 and n522 for each) between the
HEK-293 cell and the PBMC assays. Collectively, these results
indicate a high degree of consistency in the responses of this small
subset of a-Gal A mutant forms as assessed in the in vitro HEK-
293 cell-based assay and in male patient PBMC a-Gal A responses
after oral administration of AT1001.
Discussion
AT1001 (migalastat hydrochloride, 1-deoxygalactonojirimycin)
is a pharmacological chaperone for a-Gal A that is in Phase 3
clinical development as a potential therapy for Fabry disease.
AT1001 selectively binds and stabilizes a-Gal A, increasing total
cellular levels and activity for some mutant forms (defined as
‘‘responsive’’). In general, missense mutations in GLA often lead
to the expression of responsive mutant forms of a-Gal A and
constitute approximately 60% of all known Fabry disease-causing
mutations (more than 600 have been identified to date)
[Benjamin et al., 2009; Fan et al., 1999a; Ishii et al., 1996, 2007;
Lemansky et al., 1987; Shin et al., 2008; Yam et al., 2005, 2006].
In the current study, we developed a cell-based assay in HEK-293
cells to identify missense mutant forms of a-Gal A that are
responsive to AT1001. Furthermore, we demonstrated that the
responses seen in this assay can identify mutant forms of a-Gal A
that respond to AT1001 inpatient-derived cell lines and in PBMCs
of Fabry patients administered the drug.
The assay was designed to test the ability of AT1001 to increase
the total cellular activity of different mutant forms of a-Gal A
following expression in HEK-293 cells. The specific effect of
AT1001 on the expressed mutant form of a-Gal A was determined
by subtraction of the endogenous HEK-293 cell wild-type a-Gal A
activity as a function of AT1001 concentration. Thus, increased
mutant a-Gal A activity in HEK-293 cell lysates after incubation
with AT1001 indicated increased total cellular levels of the a-Gal A
mutant form. We used this approach to test 81 different Fabry
disease-associated missense mutant forms that were represented in
our collection of male Fabry patient-derived lymphoblasts and in
male patients enrolled in Phase 2 clinical trials of AT1001. AT1001
mediated significant increases in the a-Gal A levels of approxi-
mately 60% (49 of the total 81) of the mutant forms. These
mutant forms represented a wide range of baseline a-Gal A levels,
and responded with a range of relative increases in a-Gal A levels,
and EC50 values, consistent with results from Fabry patient cell
lines [Benjamin et al., 2009; Shin et al., 2007, 2008]. a-Gal A
protein structural mapping of the amino acid residues affected by
the 81 missense mutations did not identify obvious structural
determinants that could be used to consistently predict the
mutant a-Gal A response to AT1001 [Garman, 2007; Garman and
Garboczi, 2004; Matsuzawa et al., 2005; Shabbeer et al., 2006].
Collectively, these results further support the need for empirical
testing of each Fabry disease-associated mutant form to identify
those that are responsive to AT1001 [Benjamin et al., 2009; Shin
et al., 2007, 2008].
For the subset of mutant forms that were also tested by Western
blot, those that showed increased a-Gal A activity after incubation
with AT1001 also consistently showed increased a-Gal A protein
levels. Interestingly, the Western blot results revealed increased
protein levels for some mutant forms that did not show an
increase in activity (e.g., C94S). These mutant forms also did not
have measurable baseline activity, suggesting little to no catalytic
activity; however, we cannot rule out the possibility that these can
metabolize the natural substrate, GL-3 in the natural cellular
environment. These results suggest that AT1001 may have the
ability to bind, stabilize, and promote lysosomal trafficking of
some catalytically incompetent mutant forms. If mutant a-Gal A
accumulation in the ER leads to cellular stress and contributes
further to cellular dysfunction and disease [Ishii et al., 1996], it is
interesting to speculate whether this may be another mechanism
through which AT1001 could have therapeutic benefit. This may
warrant further study.
The responses of 75 different mutant forms of a-Gal A to AT1001
that were seen in the HEK-293 cell-based assay were generally
consistent with those observed in male Fabry patient lymphoblast
cell lines [Benjamin et al., 2009]. In this comparison, 90% of the
mutant forms that were responsive in male Fabry patient
lymphoblasts were also responsive in HEK-293 cells, whereas 92%
of those that were nonresponsive in male Fabry patient lympho-
blasts were also not responsive in HEK-293 cells. Furthermore,
baseline and maximum a-Gal A activity, as well as the potency of
the AT1001-mediated response were significantly correlated between
974 HUMAN MUTATION, Vol. 32, No. 8, 965–977, 2011the two in vitro assays. This further indicates that the response to
AT1001 predominantly depends on the mutant form of a-Gal A
that is expressed, and in general, is not dependent on differences in
cell type, expression level, or source of the gene [Asano et al., 2000;
Benjamin et al., 2009; Fan et al., 1999b; Ishii et al., 2007; Shin et al.,
2007, 2008]. However, the responses to AT1001 did differ for seven
of the mutant forms. In lymphoblasts, five of these mutants (N34S
[c.101A4G], R100K [c.299G4A], D170V [c.509A4T], C172Y
[c.515G4A], and P205R [c.614C4G]) showed low baseline
activity (generally o1% of wild-type) and small increases in a-
Gal A levels (below 3% of wild type), or relatively high EC50 values
(4300mM) [Benjamin et al., 2009]. In HEK-293 cells, no enzyme
activity was quantifiable at baseline or after AT1001 incubation for
these mutant forms. Thus, although the response outcomes were
somewhat different, importantly, both assays did consistently show
low enzyme activity and minimal or no response to AT1001 for
these mutant forms. The differences in response that were seen may
have resulted from subtle assay-related differences (e.g., cellular
background, gene source, expression level, or assay sensitivity at the
limit of quantification), suggesting that these mutant forms are
severely impaired with a very limited capacity for pharmacological
chaperone rescue. On the other hand, two mutant forms (G128E
[c.383G4A] and G183S [c.547G4A]) showed responses only in
the HEK-293 cells, but not in lymphoblasts. The difference in
response of G183S is likely due to the underlying nucleotide change
at the genomic level that leads to a splicing aberration [Lai et al.,
2003], resulting in a severely altered a-Gal A protein sequence in
patient lymphoblasts. The nucleotide change at the cDNA level,
however, leads to a straightforward single amino acid residue
change in the a-Gal A protein sequence, which is the mutant form
tested in the HEK-293 cell-based assay. The reason for the difference
in the G128E response to AT1001 is less clear. G128E was not
responsive in the lymphoblasts, consistent with results from other
male patient cell lines with the same mutation [Shin et al., 2008]. It
is possible that this mutation at the genomic level may also lead to
additional defects, such as aberrant splicing or instability of the
mRNA transcript.
It should also be noted that every normal lymphoblast line
tested showed a concentration-dependent increase in wild-type
a-Gal A levels in response to AT1001 [Benjamin et al., 2009].
Similarly, endogenous a-Gal A in HEK-293 cells is responsive to
AT1001 (as measured by enzyme activity and Western blot; data
not shown), and therefore its activity as a function of AT1001
concentration must be subtracted from that of each mutant
form in the HEK-293 cell-based assay. In contrast, transiently
transfected wild-type a-Gal A resulted in very high baseline levels
of activity that did not consistently show a concentration-
dependent increase after incubation with AT1001. This effect
may be due to high-level expression of a-Gal A by the transfected
HEK-293 cells that leads to saturation of the cellular machinery
that regulates folding and/or trafficking of the enzyme, thus
preventing any further increase with AT1001.
Most importantly, the responses to AT1001 of 19 different a-
Gal A mutant forms in the HEK-293 cell-based assay were
generally consistent with observed increases in a-Gal A activity in
PBMCs from male Fabry patients orally administered AT1001
during Phase 2 clinical studies. In this comparison, every mutant
form of a-Gal A that did respond in Fabry patient PBMCs also
showed a response to a clinically achievable concentration of
AT1001 (10mM) in the HEK-293 cell-based assay. Eighty-eight
percent of those that did not respond in Fabry patient PBMCs also
did not respond to AT1001 in the HEK-293 cell-based assay.
Furthermore, the baseline a-Gal A activity and the a-Gal A
activity after treatment with AT1001 were significantly correlated
between the HEK-293 cell-based and the in vivo assays. These
observations suggest that the mutant a-Gal A responses to a
clinically achievable concentration of AT1001 in the HEK-293 cell-
based assay can identify mutant forms of a-Gal A that are likely to
respond to AT1001 in vivo.
The degree of consistency found in the current comparison of
HEK-293 cell-based and in vivo mutant a-Gal A responses does not
necessarily indicate the degree of consistency that would be seen
with any particular dose or regimen of AT1001. This is because the
in vivo a-Gal A responses analyzed here were obtained following
the administration of different AT1001 doses (50, 150, or 250mg)
and with various regimens (every other day, twice per day, or every
day), according to the different clinical study protocols. Although it
is possible that some mutant forms might show a limited response
at a lower dose and a larger response at a higher dose, our results
indicate that most mutant forms that were tested at both lower and
higher doses showed a ‘‘good’’ response at either dose. This suggests
that a single common dose and regimen of AT1001 may be
sufficient to mediate a response of the enzyme in vivo for many
mutant forms of a-Gal A.
Fabry patients with responsive mutant forms of a-Gal A
potentially are most likely to benefit from AT1001 treatment. Thus,
several approaches have been considered to determine if a candidate
patient’s disease-associated mutant form of a-Gal A is likely to be
responsive to AT1001. These involve measurement of the residual
a-Gal A activity (e.g., in PBMCs or plasma), the a-Gal A response
to AT1001 in vivo or ex vivo in primary cultured T cells, and/or the
urine GL-3 response to AT1001 following oral administration
[Benjamin et al., 2009; Desnick et al., 2001; Ishii et al., 2007]. These
approaches may be limited by a lack of consistency with the in vivo
response of the patient’s a-Gal A mutant form, or exposure to
AT1001 before the potential for therapeutic benefit is known. Most
importantly, these approaches do not provide meaningful results
for many female Fabry patients. As Fabry disease is X-linked, female
patients are mosaic, harboring a mixture of cells that express either
wild-type or mutant a-Gal A. In samples derived from female
patients, the measured a-Gal A activity is dominated by the wild-
type enzyme, which is responsive to AT1001; hence, neither the
baseline activity nor the effect of AT1001 on the mutant form can
be accurately determined. Importantly, in contrast to female patient
cell lines or samples, the a-Gal A responses determined in the HEK-
293 cell-based assay are purely the response of the heterologously-
expressed mutant form.
Male Fabry patients express one mutant copy of the GLA gene
in all cells. Thus, a-Gal A responses to AT1001 in males could be
determined in vivo or in cultured cells and used to select female
patients with the same mutation; however, the a-Gal A response
to AT1001 from male patients or male cell lines is available for
only a limited number of mutant forms [Benjamin et al., 2009].
Recently, a computational approach to predicting the mutant
a-Gal A response based on protein sequence has been proposed
and could be applicable for selection of female Fabry patients; but
comparison to responses measured in male patient cell lines
showed relatively low positive predictive value and sensitivity
(0.66 and 0.49, respectively), whereas a comparison to in vivo
responses was not available [Andreotti et al., 2010]. Although the
more conventional measurement of urine GL-3 has also been
considered, baseline substrate levels are often within the normal
range in females [Kitagawa et al., 2005, 2008; Vedder et al., 2008],
thereby making it difficult to measure the effect of AT1001 based
on this endpoint. Thus, the selection of female Fabry patients
continues to warrant a test for the AT1001 response of the a-Gal A
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be a useful complementary approach.
The degree of consistency between the HEK-293 cell-based and
in vivo responses of a-Gal A mutant forms should continue to be
assessed in future studies that include a larger number of mutant
forms. Preferably, the clinical studies would assess the effect of
a fixed dose and regimen of AT1001 on a-Gal A levels in vivo,
and would also include different patients that harbor the same
mutation to assess the consistency of the intersubject mutant
a-Gal A response. Furthermore, criteria that define the threshold
response to a clinically achievable concentration in the HEK-293
cell-based assay should be refined to better identify those mutant
forms that are most likely to respond to AT1001 in vivo. It may be
challenging to obtain the highest degree of consistency between
the HEK-293 cell-based and in vivo results for mutant forms with
responses to AT1001 that are more dependent on other factors
such as different cell or tissue types, mutant a-Gal A expression
levels, or subtle differences in the target tissue concentration of
AT1001. Furthermore, the relationship between the in vivo a-Gal
A response and clinical efficacy remains to be determined.
Although increases of 1 to 5% of normal enzyme activity in vivo
have been suggested to be clinically meaningful [Conzelmann and
Sandhoff, 1983; Desnick, 2004], the threshold level of increase that
will lead to clinical efficacy is currently unknown. In addition,
clinical efficacy can be affected by other factors, such as disease
severity, extent of disease progression at the start of treatment,
individual differences in AT1001 exposure levels at a given dose,
and/or genetic modifiers.
In conclusion, a high degree of consistency in the responses to
AT1001 of a-Gal A mutant forms determined in the HEK-293 cell-
based assay was shown in comparison to the in vivo responses
assessed in PBMCs of male Fabry patients orally administered
AT1001 during Phase 2 clinical trials. This indicates that the
responses to a clinically achievable concentration of AT1001 in the
HEK-293 cell-based assay can identify mutant forms of a-Gal A
that are likely to respond to AT1001 in vivo. Thus, the HEK-293
cell-based assay may prove to be a useful complementary aid in
the identification of Fabry patients with AT1001-responsive
mutant forms. Further evaluation of the utility of the HEK-293
cell-based assay for Fabry patient selection for treatment with
AT1001 is ongoing.
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